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Reactivation of cutaneous and mucocutaneous tegumentary 
leishmaniasis in rheumatoid arthritis patients: an emerging 
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ABSTRACT 
Rheumatoid arthritis (RA) is a chronic condition that is frequent in patients living in 
tropical areas exposed to leishmaniasis. RA therapy involves immunosuppressant drugs 
such as methotrexate (MTX), monoclonal antibodies (mAbs) and prednisone. We report 
an unusual presentation of cutaneous (CL) or mucocutaneous leishmaniasis (ML) in RA 
patients from an endemic area of leishmaniasis. A 51-year-old woman noted a cutaneous 
ulcer on her left ankle during MTX and prednisone RA therapy. Initially diagnosed as a 
venous stasis ulcer, the aspirate of the injury revealed the presence of Leishmania DNA. A 
73-year-old woman presenting non-ulcerated, infiltrated and painful erythematous nodules 
inside her nostrils while receiving MTX, anti-TNF mAb, and prednisone for RA, had also the 
aspirate of injuries showing the presence of Leishmania DNA. Both patients healed after the 
therapy with liposomal amphotericin. The RA therapy has changed to low-dose prednisone, 
without further reactivation episodes. Both cases suggest that CL or ML can reactivate after 
administration of an immunosuppressant for RA treatment. Therefore, immunosuppressive 
treatments for RA should be carefully prescribed in patients from endemic areas or with a 
history of CL and ML. 
KEYWORDS: Leishmaniasis. Reactivation. Methotrexate. Anti-TNF mabs. Rheumatoid 
arthritis.
INTRODUCTION
Leishmaniasis is an anthropozoonosis caused by Leishmania species and can 
have different clinical presentations depending on the parasite-host relationship1. 
The most common species of Leishmania in Brazil are L. (Viannia) braziliensis, 
L. (Leishmania) amazonensis, and L. (V.) guyanensis, followed by the uncommon 
species L. (V.) naiffi, L. (V.) lainsoni, L. (V.) shawi, and L. (V.) lindenbergi2. 
Leishmania (V.) braziliensis has been more frequently found in the South and 
Southeast regions of Brazil. 
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis are widely 
distributed in Brazil, and although they are considered to be less severe than the 
visceral forms, they produce cutaneous (CL) and/or mucosal (ML) lesions capable 
of mutilating or stigmatizing the patients, making the social inclusion of affected 
individuals difficult. 
The lesions appear primarily in uncovered areas of the skin, often as ulcers with 
well-defined edges and a granular bottom. In some individuals, the patient may also 
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experience lesions of the mucosal tissue, especially of the 
upper respiratory and digestive tract, producing discomfort 
swallowing or breathing. Oftentimes, the infections are 
chronic and can reactivate several times during the patient’s 
life, since parasites are known to persist at the lesions3,4. 
Rheumatoid arthritis (RA) therapy is a rapidly 
evolving area of study involving the use of potent 
immunosuppressant drugs, such as methotrexate, and anti-
cytokine immunobiologicals5. In addition to the classical 
prednisone therapy, these newer strategies have significantly 
modulated the host immune response, increasing the 
patient’s susceptibility to infections, such as leishmaniasis6. 
Herein, we present two patients with reactivated cutaneous 
or mucocutaneous leishmaniasis after immunosuppressive 
therapies against RA, and discuss that the specific therapy 
for RA must consider the risk for CL or ML leishmaniasis 
reactivation.
CASE PRESENTATION
Case report 1 
A 51-year-old Brazilian woman presented with a 
cutaneous ulcer on her left ankle and was treated in the 
Division of Infectious and Parasitic Diseases, Hospital 
das Clínicas, University of São Paulo, Medical School, 
São Paulo, Brazil. She reported had been receiving various 
drugs to control rheumatoid arthritis, diagnosed several 
years before. The treatment schedule included 25 mg of 
methotrexate intramuscularly once a week for two years, 
5 mg of prednisone orally and daily for five years, and 
chloroquine 400 mg orally and daily for two years. During 
her childhood, the patient used to live in an endemic county 
for cutaneous leishmaniasis (São Lourenço da Serra – São 
Paulo) and described the presence of a long-lived skin ulcer, 
which had appeared at that time and diagnosed as cutaneous 
leishmaniasis. At examination, the lesion presented as a 
painful, foul smelling, and edematous 8 cm-diameter ulcer 
in the fibular malleolus region, which showed fibrin but 
without infiltrated edges (Figure 1A). Another atrophic 
circular scar has also been found on the left pretibial 
region. Histology of the biopsy obtained from the border 
of the lesion was compatible with a venous stasis ulcer 
with intense granular tissue and scarring (Figure 1B). The 
patient had started empirical treatment with piperacillin, 
tazobactam and clindamycin. The patient developed fever, 
but with no growth in blood cultures. The patient’s treatment 
was altered to imipenem 500 mg/ day for 7 days resulting in 
improvement in the patient’s condition and renal function. 
During the investigation, Leishmania PCR analysis from 
the aspirate of the lesion was positive (Figure 1C), resulting 
in treatment with 3 mg/kg/day of a liposomal amphotericin 
protocol for ten days (total cumulative dose of 35 mg). 
The possible reactivation of the cutaneous leishmaniasis 
diagnosed during her childhood was considered at this 
point. During the last few doses, amphotericin treatment 
was discontinued due to worsening of the renal function, 
but the treatment was completed after dose adjustments 
for 2 mg/kg/day. In addition, to control RA, 20 mg/day 
of leflunomide was introduced after the rheumatologist 
evaluation. After the treatment with amphotericin was 
finished, the cutaneous ulcer on the left ankle of the patient 
had clearly improved without fibrin, as noted through visual 
inspection. At this time, the patient was discharged from 
hospital and continued to be monitored at her hometown 
until the ulcer had completely healed (Figure 1D).
Case report 2 
A 73-year-old Brazilian woman was admitted to the 
medical service presenting a lesion on her face (Figure 2A). 
She had a history of leishmaniasis at the age of nine 
years-old. Four years ago, she presented with painful 
erythematous nodules on her face, more precisely in the 
nasal passages, nose, and perioral region. The lesions were 
diagnosed as mucocutaneous leishmaniasis and treated with 
20 mg/kg/day of pentavalent antimony (Glucantime®) for 
twenty-eight days, resulting in their disappearance. After 
a nasofibroscopy, it was determined that the patient was 
clinically cured. However, six months ago, she began to 
suffer from pain in her face and the reappearance of the 
infiltrated erythematous nodules, which were very similar 
to those that had appeared 4 years before. The patient was 
again hospitalized, and during anamnesis, she reported 
that she had received a weekly treatment for rheumatoid 
arthritis with 7.5 mg of methotrexate, 6 mg of prednisone, 
100 mg of chloroquine, and 50 mg/month of golimumab. 
At this time, the small erythematous lesions had become an 
infiltrated plate in the septal region associated with ulcerated 
areas with intranasal crusts. The patient began an empirical 
treatment for rhinitis with nasal topical medication. 
The lesion progressively evolved, and the Montenegro 
intradermal test showed a 15-mm diameter induration. 
A diameter of ≥ 5 mm indicates a positive reaction. The 
Montenegro intradermal test is useful in cases in which the 
parasites are scarce or absent in the lesions, i.e., when acute 
cutaneous leishmaniasis lesion has undergone more than 2 
months of evolution and spontaneous healed7. Histological 
evaluation (HE) of the biopsy border showed Leishmania 
amastigotes and an inflammatory infiltrate (Figure 2B). 
kDNA-PCR analysis of the lesion aspirate showed the 
presence of Leishmania sp. The amplification product of the 
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kDNA-PCR was subjected to Restriction Fragment Length 
Polymorphism (RFLP) and the profile was compatible with 
L. (V.) braziliensis ((fragments of 40 and 80 bp)8, as seen in 
the Figure 2C, confirming the diagnosis of ML.  Thirty-five 
mg/kg of liposomal amphotericin B was used for treatment. 
After the fourth infusion, laboratory tests revealed that 
the patient had nephrotoxicity manifested with polyuria, 
leading to a daily correction of doses, ultimately resulting 
Figure 1 - Lesion on the left ankle of patient 1 before therapy at biopsy (1A); histology of the initial biopsy (1B) showed granulated 
tissue and signs of venous stasis (HE x400); kDNA-PCR analysis amplified a 120-bp fragment (1C); the lesion after completing 
anti-leishmanial and antimicrobial therapy is shown (1D).
Figure 2 - Induration and crusting on the nasal areas of the lesion of patient 2 at admission (2A); results of histology (2B) (HE 
x400); PCR-RFLP (2C) showing the 80 and the 40-bp fragments, and the lesion after completion of Leishmania-specific therapy 
is shown (2D).
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in improved renal function. The rheumatology group 
advisor suggested that treatment of rheumatoid arthritis 
could be maintained only with 10 mg/day of prednisone 
administered twice a day (5 mg/dose) to prevent adrenal 
insufficiency. After receiving a cumulative dose of 2,500 
mg of amphotericin B, the patient showed a significant 
clinical improvement (Figure 2D), when compared to 
Figure 2A. At this time, she was discharged from hospital 
and was followed at the outpatient clinic for treatment 
and surveillance of her leishmaniasis, perioral lesions 
and RA. 
DISCUSSION
We described two confirmed cases of reactivated CL 
or ML leishmaniasis in two patients who lived in endemic 
areas, had a history of previous contact with the Leishmania 
parasite and were under immunosuppression due to 
therapy for rheumatoid arthritis. The first case appears 
to be a reactivation of a single cutaneous leishmaniasis 
lesion due to parasites that remained in the old scar, after 
immunosuppression. In case 2, there was reactivation of 
mucosal leishmaniasis, which has been associated with 
hyperactive immune responses in immunocompetent 
patients. However, mucosal lesions can also be found 
in HIV-AIDS co-infected patients9, suggesting that the 
deregulation of the specific immune response, as produced 
by mAb therapy, can play a role in the lesion development. 
The lesions of both patients resolved with anti-leishmania 
therapy, and the RA treatments were adjusted to decrease 
the level of immunosuppression. 
The immune response can either favor, cure, or lead to 
disease development, depending on its quality and intensity. 
When immunosuppression is present, this instability affects 
the patient’s immune control of pathogens or cancer 
cells. Consequently, the development of severe infections 
or neoplasia can take place. On the other hand, when 
hyperactivity is present, allergies, autoimmune diseases, 
and uncontrolled tissue damage become common. 
In this context, what can occur when both branches are 
present? Cutaneous and mucosal leishmaniasis stimulate 
a predominant type 1 immune response, characterized 
by a high-level of IFN-γ and TNF-α secretion10. Th1 
immune responses, although associated with the control 
of parasite multiplication and dissemination, can cause 
tissue damage if they are not modulated11,12. The protozoa 
can persist alive in the scars of ancient lesions for years, 
sustained by a persistent, well-modulated Th1 local immune 
response pattern, even after treatment4. A role for TNF-α 
in the pathogenesis of mucosal leishmaniasis and other 
chronic inflammatory parasitic diseases is suggested by 
the increased levels of TNF-α in sera11, the high expression 
levels in mucosal tissue13, and the decreased TNF-α levels 
after therapy of mucosal leishmaniasis14. The literature 
suggests that the reactivation of leishmaniasis is associated 
with the deregulation of the specific immune response as 
a decrease in inflammatory cytokines (IFN-γ and TNF-α) 
and an increase of cytokines associated with the Th2 
immune response (IL-4 and IL-10)15. An early prospective 
study published in 1994 suggested that patients receiving 
methotrexate had a higher risk of serious infection than 
those not receiving the drug, RR 1.52 (95% CI 1.04 - 2.13)16. 
Data from the US CORRONA study group (http://www.
corrona.org) found a similarly increased risk of infection 
and an incidence rate ratio of 1.30 (95% CI 1.12, 1.50) in 
a prospective follow-up of a cohort of 7,971 RA patients 
when comparing MTX with other disease modifying anti-
rheumatic drugs (DEMARDs). There is also a reported 
case of tuberculous pericarditis complicated by cardiac 
tamponade in an elderly patient on methotrexate treatment 
for rheumatoid arthritis17. Anti-TNF-α therapy has also 
been associated with an increased risk for developing 
opportunistic infections18 such as Pneumocystis jirovecii 
pneumonia, histoplasmosis, cytomegalovirus infections, 
aspergillosis, cryptococcal meningitis, leishmaniasis, and, 
in particular, tuberculosis19. 
Despite an increase amount of information, most 
physicians still have problems associating the presence 
of cutaneous and mucosal lesions with infection or 
reactivation of CL or ML leishmaniasis in patients 
under immunosuppressive treatment. These patients 
may have some epidemiological evidence of previous 
leishmaniasis, but are, at the time of diagnosis, living in 
non-endemic regions of neglected tropical diseases. In this 
context, it is still necessary to emphasize the possibility 
of the immunossupressive treatment be responsible for 
reactivating leishmaniasis, primarily in older people living 
in non-endemic areas/ countries but also in patients with a 
history of living or traveling to CL and ML-endemic areas. 
Reports from a non-endemic country, such as the USA, 
have shown that the infection rates are the highest among 
previously exposed immigrants from endemic areas20,21.
CONCLUSIONS 
Immunosuppressive treatments for RA could be 
associated with reactivation of cutaneous or mucocutaneous 
leishmaniasis. Our reported cases must alert physicians 
from non-endemic regions/ countries to the possibility of 
leishmaniasis whenever unusual infections occur in patients 
starting immunosuppressant RA treatment, especially when 
they have previously lived abroad, and in older, migrant 
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patients. This problem calls for increased information, 
surveillance, and the availability of diagnosis and treatment 
of cases, which is difficult in non-endemic countries. 
Information from RA immunosuppressive treatment with 
disease-modifying anti-rheumatic drugs (DMARDs) and 
biologicals, such as mAbs, must alert physicians to the risk 
of reactivation of latent CL and ML leishmaniasis in patients 
who lived or traveled to leishmaniasis-endemic areas.
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